Acanthocheilonema viteae is a species of parasitic nematodes from the family Acanthocheilonematidae, also known as “human filariasis” or “filariasis”. It is found in Africa, Asia, the Pacific islands, and the Americas and typically affects the lymphatic system. They are typically spread by infected mosquitoes, and the disease can cause fever, fatigue, joint pain, and swelling. In severe cases, it can cause elephantiasis, which is a swelling of the legs and arms. Treatment includes medications such as anti-parasitic drugs, antibiotics, and anti-inflammatory medications.

One of the most interesting aspects of Acanthocheilonema viteae is the antigen Av33, which is produced by the worm and has been found to play a key role in its survival and infectivity. Av33 has also been identified as a potential target for vaccines and therapeutics, as it is unique to the parasite and not found in other organisms.

In addition to Av33, Acanthocheilonema viteae produces the protein Fatty-acid and retinol-binding protein 1, which is involved in the transport of lipids and retinoids in the worm’s body. This protein has also been studied for its potential as a therapeutic target, as it is essential for the parasite’s survival and may be vulnerable to disruption.

While Acanthocheilonema viteae is primarily a parasite of rodents, its study has important implications for human health. Filarial worms like Acanthocheilonema viteae can cause serious diseases in humans, including lymphatic filariasis and onchocerciasis, which affect millions of people worldwide. By understanding the biology of these parasites and developing new treatments and prevention strategies, we can work to reduce the burden of these diseases and improve the health of affected individuals.

The use of recombinant proteins/cDNA in academic research and therapeutic applications has skyrocketed. However, in heterologous expression systems, successful recombinant protein expression is dependent on a variety of factors, including codon preference, RNA secondary structure, and GC content. When compared to pre-optimization, more and more experimental results demonstrated that the expression level was dramatically increased, ranging from two to hundred times depending on the gene. Bioclone has created a proprietary technology platform that has resulted in the creation of over 6,000 artificially synthesized codon-optimized cDNA clones (cloned in E. coli expression Vector), which are ready for production of the recombinant proteins.

Acanthocheilonema viteae cDNA and recombinant antigen can be used to develop a variety of diagnostic tools and vaccines for the control of human filarial infections. Diagnostic tools include the use of PCR-based assays to detect the presence of A. viteae DNA in clinical samples. Recombinant antigen can be used to develop ELISA assays to detect circulating antibody responses to A. viteae. Vaccines can be developed to induce immunity against the parasite, which may be used for the prevention and control of filarial infections.